KP-1212
| Code | Size | Price |
|---|
| TAR-T32418-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32418-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32418-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
KP-1212( SN-1212) is a nucleoside designed for the treatment of HIV by viral mutagenesis.
CAS:
114522-16-6
Formula:
C8H14N4O4
Molecular Weight:
230.224
Purity:
0.98
SMILES:
NC1=NC(=O)N(CN1)[C@H]1C[C@H](O)[C@@H](CO)O1
References
1. Rawson JM, Heineman RH, Beach LB, Martin JL, Schnettler EK, Dapp MJ, Patterson SE, Mansky LM. 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem. 2013 Nov 15;21(22):7222-8. doi: 10.1016/j.bmc.2013.08.023. PubMed PMID: 24120088; PubMed Central PMCID: PMC3930610.
2. Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005 Jul;67(1):1-9. PubMed PMID: 15890415.
3. Clay PG, McRae M, Laurent JP. Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults. J Int Assoc Physicians AIDS Care (Chic). 2011 Jul-Aug;10(4):232-8. doi: 10.1177/1545109711406442. PubMed PMID: 21593403.
4. Peng CS, Fedeles BI, Singh V, Li D, Amariuta T, Essigmann JM, Tokmakoff A. Two-dimensional IR spectroscopy of the anti-HIV agent KP1212 reveals protonated and neutral tautomers that influence pH-dependent mutagenicity. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3229-34. doi: 10.1073/pnas.1415974112. PubMed PMID: 25733867; PubMed Central PMCID: PMC4371980.